For worn joints and lasting pain — an option to "support" with your own cells.
Before relying on surgery or medication alone. With your own MSCs (mesenchymal stem cells), a path that supports tissue repair — where a physician checks imaging, blood tests, medical history, cancer history, and cell quality one by one, and works with you to see whether it fits. This is not a treatment recommended for everyone — which is exactly why we move forward only when it suits you.
Entry: MSC eligibility review (imaging + blood tests + physician assessment) / cost shared individually at physician consultation (self-pay) / pharmaceutical-grade quality records and provenance reviewed / shared before your visit by LINE or email.
What to send, what we confirm,
and which options you discuss with a physician.
Whether MSC fits is decided by a physician who checks imaging, blood tests, medical history, and cell quality one by one. You do not need every document ready first — you can start a records consultation with whatever you can send.
- MRI / X-ray images, or a radiology report
- Health-check, full medical check-up, or blood-test data
- Medications and medical history (including cancer-treatment history and autoimmune disease)
- Where and when it hurts, and your treatment history so far
You do not need every document ready. Send what you have, and we can begin a records consultation by email.
We organize MRI findings, pain, range of motion, and treatment history. Imaging alone does not finalize a treatment plan.
We read inflammation, metabolism, and history together with test data. Test values alone do not decide suitability.
We organize where treatments you have already had, and other options, fit. When needed, consultation with a specialist or your attending physician is a prerequisite.
As a filed provision plan, a physician confirms whether MSC could become an option to consider. It is not a treatment that suits everyone, and cancer history in particular is judged with special care.
Based on the records, a physician organizes which options to consider. Suitability is decided individually by a physician.
Even when the word is "MSC," source and process records are not all the same.
MSC means mesenchymal stromal / stem-cell related consultation, but the records that can be traced differ by tissue source, collection method, culture process, and quality-confirmation items. The point is not cell count alone. Source, origin, lot identity, process records, storage, transport, and consent explanation need to be reviewed together.
At the clinic, cell processing is handled through contracted cell-processing facilities under a quality-management-oriented framework. Process records and quality documents are explained within the range the physician can review. Materials with unclear source or insufficient quality documentation are not treated as a basis for explanation and consent.
A filed / notified status describes the provision framework under Japan's Regenerative Medicine Safety Act. It is not a promise of individual treatment outcome. Costs, main risks, and scheduling are explained individually during consultation.
Fresh, frozen, and banked MSC require different checks.
Patients may hear terms such as fresh / non-frozen, cryopreserved / frozen, thawed, or banked MSC. These words describe handling and documentation routes. They do not mean that one route is automatically better or suitable for every person.
Timing is the main review point.
This route is considered only when the processing, transport, and administration schedule supports it. Timing, transport, identity, sterility checks, and release judgment must be confirmed before administration.
Thaw and storage records matter.
Cells may be frozen for storage, transport, or scheduling. The physician reviews thaw handling, post-thaw viability, expiry or handling window, storage-temperature records, and lot / release documents.
Later use still needs re-checking.
When a patient's own cells are harvested, processed, and stored for later review, identity, infection screening, lot records, sterility, endotoxin, mycoplasma results, and renewed consent are checked before later use.
These are quality-review categories. They are not proof of clinical effect and do not remove risk. An MSC option should not be judged by name, cell count, or price alone.
What should be checked before MSC is discussed.
Imaging and symptoms
For knee and joint concerns, MRI findings, pain pattern, range of motion, and previous treatment history are reviewed. If MSC is not suitable, other options may be discussed.
Bloodwork and history
Infection status, inflammation, liver and kidney function, coagulation, metabolism, cancer-treatment history, autoimmune disease, and medications are organized before any treatment discussion.
Cell quality
The physician explains cell source, processing, culture, quality confirmation, administration route, schedule, cost, and main risks within the scope of the available documents.
The physician decides within the Category II regenerative-medicine framework.
MSC stem-cell treatment is handled within the Category II regenerative-medicine framework under Japan's Regenerative Medicine Safety Act. Filed / notified status describes the provider framework. It does not promise an individual treatment result.
For knee consultations, 3T knee MRI and physician assessment are combined. The physician then organizes whether MSC consultation is reasonable, whether orthopedic referral is more appropriate, whether monitoring is needed, or whether additional testing should come first.
MSC consultation for chronic pain
MSC consultation for chronic pain. Intravenous infusion may be included. Filed provision-plan numbers: PB3240161 / PB3250154.
Symptoms, history, medications, imaging, and bloodwork are reviewed before the physician makes an individual judgment.
MSC consultation for knee and joint concerns
MSC consultation for osteoarthritis. Intra-articular administration may be included. Filed provision-plan numbers: PB3240166 / PB3250155.
Cell-quality review
Beyond cell count, the clinic organizes quality, culture process, cell-aging considerations, and purpose-specific review points for physician explanation.
Self-pay private care and risk explanation.
MSC stem-cell treatment is self-pay private care and is not covered by Japanese public health insurance. Fees, main risks, expected schedule, and treatment route are explained individually during consultation.
Whether treatment can be provided, the administration route, number of sessions, and cell-processing flow are determined by the physician after reviewing test results and medical history. The page does not promise any specific result.
First confirm whether consultation is appropriate, not whether you will receive MSC.
If you already have imaging, blood-test results, medication records, or medical history notes, bringing them together before the visit can make the physician consultation smoother.
What to know before asking about MSC.
Can MSC stem-cell treatment be provided on the same day as the consultation?
No. The physician first reviews imaging, blood tests, medical history, cancer-treatment history, and medication details, then decides individually whether MSC consultation can proceed. Treatment feasibility, administration route, number of sessions, cost, main risks, and schedule are explained during consultation.
How is MSC quality reviewed?
It is not reviewed by cell count alone. Source, origin, collection method, culture process, lot identity, process records, storage, transport, and consent materials are organized. Cell processing is handled through contracted cell-processing facilities under a quality-management-oriented framework, and records are reviewed within the range the physician can explain.
Do "Category II" and "filed / notified" mean that efficacy has been approved?
No. They describe the provision framework under Japan's Regenerative Medicine Safety Act. They are not an approval of individual efficacy and do not promise treatment outcomes. Filed provision plans can also be checked through Japan's public registry.
Which concerns can be discussed for MSC? Is it only for knees?
The clinic handles filed provision plans for MSC consultation related to chronic pain, including possible intravenous infusion, and for osteoarthritis, including possible intra-articular administration. For knee concerns, 3T knee MRI and physician assessment are combined to organize whether MSC consultation is reasonable and what other options should be considered. Suitability is judged individually by the physician.
How are MSC, NK cells, and EV / exosome consultations different?
The cells or products are different, and the required documents and filed provision-plan context are different. Each page organizes source, quality documents, and physician-explanation prerequisites. Whether multiple options should be considered is also explained only after tests and records are reviewed.
Related pages and next reading.
Public registry and official channels.
These links point to Japan's public registry pages for filed regenerative-medicine provision plans and to the clinic's official YouTube / Instagram channels. Registry publication is a reference for filed provision-plan information; it is not evidence of individual treatment outcomes and does not remove risk.